Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.45 |
| ▸ | CA2 | P00918 | 9/20 | 0.45 |
| ▸ | CA12 | O43570 | 8/20 | 0.45 |
| ▸ | CA7 | P43166 | 7/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA6 | P23280 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 7/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677588 | 0.86 | CA1 (0.52) | CA1CA2CA12CA7CA13 | |
| SCHEMBL28499567 | 0.83 | PKM (0.44) | CA1CA2CA12CA7CA9 | |
| SCHEMBL12487983 | 0.78 | PTGES2 (0.49) | CA1CA2CA12CA7CA13 | |
| SCHEMBL2776043 | 0.78 | PTGES2 (0.47) | CA1CA2CA12CA7CA13 | |
| SCHEMBL13006836 | 0.77 | ACHE (0.44) | CA1CA2CA12CA7CA13 | |
| SCHEMBL3771716 | 0.77 | CA1 (0.43) | CA1CA2CA12CA7CA13 | |
| SCHEMBL2791703 | 0.77 | PKM (0.47) | CA1CA2CA12CA7CA13 | |
| SCHEMBL11237560 | 0.76 | PKM (0.39) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2542148 | 0.76 | CA2 (0.64) | CA1CA2CA12CA7CA9 | |
| SCHEMBL5353941 | 0.76 | TSHR (0.48) | CA1CA2CA12CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| EP-2234993-B1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2012-11-07 | — | — | EP | disclosed |
| CN-101945859-A | Bis-(sulfonylamino) derivatives in therapy | ASTRAZENECA AB | 2011-01-12 | — | — | CN | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| EP-2234993-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009082347-A1 | BIS- (SULF ONYLAMINO) DERIVATIVES FOR USE IN THERAPY | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163586-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 205 | PTGER1, SULT2A1, SULT1E1 | CA1 3346/4885CA2 2435/4885CA12 4390/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | CA1 3319/4885CA2 2457/4885CA12 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.